AmCyte Inc.

Cell therapy for patients suffering from diabetes mellitus

AmCyte Inc. was incorporated in 1991. In 1997 Amcyte carried out the first encapsulated porcine islet transplant in a non-immune suppressed patient and continued to develop its proprietary encapsulation technology for transplantation into patients. The first islets transplant took place in February 2005 at Toronto General Hospital.

Terrence Soon Shiong, CEO
Wen-Ghih Tsang, PhD, Senior VP Research & Development
Oliver Foellmer, Director of Business Development

Gary A. Levy, MD
Jerrold M. Olefsky, MD
Daniel Porte Jr., MD

2825 Santa Monica Blvd., Suite 200
Santa Monica, CA 90404
USA
Phone: +1-310-264-7768
Fax: +1-310-453-6948

AmCyte has developed novel encapsulation technology to allow transplantation of insulin-producing islets without chronic immune suppression. Encapsulated proliferated islet implants rely on primary pancreatic cells as starting material. Following proliferation, the cells are encapsulated into alginate. To treat patients, the encapsulated cells are infused into the peritoneal cavity of the patients.

In collaboration with the Toronto Multi Organ Transplant Program, Amcyte conducted a Phase I/II safety study of encapsulated isolated primary human pancreatic islet transplantation with low dose short-term immune suppression in patients with type-I diabetes mellitus. Preclinical results were presented in May 2004.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.